Sulfonylureas are the oral agents widely used in T2D treatment, which mechanism of action is stimulation of insulin secretion as well as of basal insulin via binding to sulfonylurea receptor 1 (SUR1). The gene discussed is INS; the disease is type 2 diabetes mellitus.